

# Head and Neck Cancers

FCDS 2011/2012 Educational Webcast Series

February 16, 2012

Mayra Espino, BA, RHIT, CTR

Steven Peace, BS, CTR

Updated for 2012 Requirements and CSv02.03.02

---

---

---

---

---

---

---

---

## Presentation Outline

- Overview
- Anatomy of Head and Neck
- Multiple Primary and Histology Coding Rules Refresher
- Collaborative Stage Data Collection System
- C.S. Site Specific Factors
- Treatment Options
- Documentation

2

---

---

---

---

---

---

---

---

## Overview



---

---

---

---

---

---


---

---

## What is head and neck cancer?

- Head and Neck Cancer is a group of cancers that includes tumors in several areas above the collar bone.

### Lip and Oral Cavity Structures



4

---

---

---

---

---

---

---

---

## Head and Neck: General Facts

- 2009 estimated US 35,720 new cases, ACS
- Men > women
- Age > 45
- 90 % of head and neck cancer are Squamous cell ca
- Originate from the mucosal lining (epithelium)
- Spread to Lymph nodes of the neck
- Lymph node of the neck often the first (and sometimes only) sign at diagnosis
- Environmental and lifestyle risk factors
  - Smoking, alcohol, virus (HPV & CMV), Hematopoieic stem cell transplantation (HSCT: Oral SCC)
  - Highly curable if detected early

<http://www.cancer.org/Research/CancerFactsFigures/index>

5

---

---

---

---


---

---


---

---

### Leading Sites of New Cancer Cases and Deaths - 2011 Estimates\*



### Leading Sites of New Cancer Cases and Deaths among African Americans



6

\*Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder

©2011, American Cancer Society, Inc., Surveillance Research

---

---

---

---

---

---

---

---

## Risk Factors

### Tobacco Products

- Smoking Tobacco
- Cigarettes
- Cigars
- Pipes
- Chewing Tobacco
- Snuff



### Other Factors:

- Ionizing Radiation
- Plummer-Vinson Syndrome
- Epstein-Barr Virus
- Human Papilloma Virus
- Chronic irritation
- Diet (lack fruits, vegetables)
- Immunosuppressive medication
- Gender

### Ethanol Products

- Alcohol
- Mouthwash containing alcohol

### Chemicals

- Asbestos
- Chromium
- Nickel
- Arsenic
- Formaldehyde



7

---

---

---

---

---

---

---

---

---

---

## Lifestyle

- Immigrants from Southeast Asia & East Indies :

paan (betel quid)

Oral cancer lip, mouth, tongue, and pharynx; and esophageal cancer



Paan (betel quid) which has been used with several other ingredients, sometimes including tobacco, pressed in a betel nut shell and chewed.

- South Americans,: mate, a tea-like beverage

- Mouth, throat, esophagus, and larynx cancer



<http://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck>

Mate. Photograph. Encyclopædia Britannica Online. Web. 29 Dec. 2011.

8

---

---

---

---

---

---

---


---

---

---

## Tobacco Use

### SOME OF THE HARMFUL CHEMICALS FOUND IN CIGARETTE SMOKE



<http://www.myquitsmokingsecrets.com/images/chemical.jpg>



9

---

---

---

---

---

---

---

---

---

---

## H&N Possible Occupational Risks

- Woodworking-
  - Wood dust as a "confirmed" human carcinogen
- Leather manufacturing-Shoe
  - Carcinogens such as polychlorophenols and their sodium salts and chromium (VI) compounds
- Nickel Refining
  - These include pulmonary and sino-nasal cancer from exposure to the dusts involved in certain, now obsolete, processes, dermatitis and nickel carbonyl poisoning
- Textile industry –
  - exposed to cotton dust, and in workers involved in spinning or weaving
- Radium dial painting- Medical exposure



*nickel briquettes*. Photograph. *Encyclopædia Britannica Online*. Web. 29 Dec. 2011. <http://www.britannica.com/EBchecked/media/120839/Nickel>

10

---

---

---

---

---

---

---

---

## Head and Neck Signs & Symptoms

### Signs

- Red or white patch in the mouth
- Oral ulceration, swelling, or loose tooth
- Lateral neck mass
- Rapidly growing thyroid mass
- Cranial nerve palsy
- Orbital mass
- Unilateral ear effusion, earache

### Symptoms

- Sore throat
  - Hoarseness
  - Stridor
  - Difficulty in swallowing
  - Lump in neck
  - Unilateral ear pain
- Many are "silent"
- No pain or other symptoms until advanced stages

11

---

---

---

---

---

---

---

---

## Head and Neck Presentations

- Persistently enlarged neck nodes in younger patients (30-50 years)
- HPV
- Persistent unilateral otalgia with no signs of ear infection in patients over 30
- Recent onset wheeze in a patient over 40, usually a heavy smoker



**Human Papillary Virus (HPV)**  
 Courtesy of Dr. Steve Debbink  
 Dental Director, AIDS Resource Ctr of Wisconsin  
[http://www.hivdent.org/\\_picturegallery\\_/HPV1.htm](http://www.hivdent.org/_picturegallery_/HPV1.htm)

12

---

---

---

---

---


---

---

---

### Human Papillomavirus (HPV)

- **DNA virus**
- Preferentially infect squamous epithelial cells
- >100 genotypes
- ≥40 genital HPV types
- The most common STD worldwide
- 80% sexually active adults in the US infected with at least one HPV type by age 50<sup>1</sup>
- Peak prevalence during adolescence and young adulthood
- **Prevalence declines with age**
- HPV 16 is the most common HR type



Centers for Disease Control and Prevention, Rockville, Md. CDC National Prevention Information Network, 2004 <http://theholisticdentist.files.wordpress.com/2011/06/hpv.jpg>

13

---

---

---

---

---


---

---

---

### Cytomegalovirus (CMV)

- Oncovirus
- Most common salivary gland cancers



<http://www.webdental.com/profiles/blogs/cytomegalovirus-cmv-confirmed-as-cause-of-salivary-gland-cancer>

14

---

---

---

---

---

---

---

---

### Head & Neck Diagnostic Workup

#### Physical Exam

- Head and Neck exam
- Mirror and fiberoptic examination as clinically indicated
- Dental Evaluation, including panorex
- HPV testing
- Nutrition, speech & swallowing evaluation/therapy and audiogram as indicated

#### Panendoscopy

- Examination under anesthesia with endoscopy as indicated
- Preanesthesia studies

#### Biopsy

- Brush
- Excisional

#### Radiology

- Chest imaging
- Ct with contrast and/or MRI with contrast of primary and neck
- Consider PET-CT for stage III-IV disease

15

---

---

---

---

---


---

---

---

## Head & Neck Diagnostic Workup

- Investigations used for H&N Cancer
- Dental Exam
- Imaging
  - Computed tomography scanning (CT)
  - Positron emission tomography (PET)



Positron emission tomography-computed tomography scans showing: left Neck  
<http://www.bmj.com/content/341/bmj.e684>

16

---

---

---

---


---

---

---

---

## Which Diagnostic Test?

CT scan	MRI	PET
<ul style="list-style-type: none"> <li>•Rapid acquisition time</li> <li>•Patient tolerance</li> <li>•Superior bone detail</li> </ul>	<ul style="list-style-type: none"> <li>•Multiple planes assess tumor volume</li> <li>•Superior soft tissue resolution</li> <li>•No IV contrast</li> </ul>	<ul style="list-style-type: none"> <li>•Entire body</li> <li>•May delineate questionable findings from other scans</li> </ul>
<ul style="list-style-type: none"> <li>•IV contrast with allergy concerns</li> <li>•Poor soft tissue contrast</li> <li>•Metallic dental applicances interfere</li> </ul>	<ul style="list-style-type: none"> <li>•Patient movement distorts</li> <li>•Bone detail inferior</li> <li>•Longer time for patient</li> <li>•Any metal may preclude</li> </ul>	<ul style="list-style-type: none"> <li>•Cost</li> <li>•Availability</li> <li>•Equivocal results may not be helpful</li> </ul> 

17

---

---

---

---

---

---

---

---

## NCCN Practice Guidelines Narrative Summary PET and PET/CT

Head and Neck Cancers (v.2.2010)

- Occult primary: PET/CT (before biopsy) (diagnosis).
- Initial staging of cancer of the oral cavity, oropharynx, hypopharynx, glottic larynx, and supraglottic larynx: Consider PET/CT for stage III-IV disease (staging).
- Initial staging of mucosal melanoma: Chest imaging or consider PET scan to rule out metastatic disease.
- Initial staging of cancer of the nasopharynx: Imaging for distant metastases (chest, liver, bone) for WHO class 2-3/N2-3 disease (may include PET scan and/or CT) (staging).
- Post-treatment evaluation of cancers of the head and neck (minimum 12 weeks): PET/CT (suggest full dose CT with IV contrast). If PET/CT is performed and negative for suspicion of persistent cancer, further cross-sectional imaging is optional (restaging).

18

[http://www.nm.org/docs/PET\\_PROS/NCCNPracticeGuidelinesll.pdf](http://www.nm.org/docs/PET_PROS/NCCNPracticeGuidelinesll.pdf)

---

---

---

---

---

---

---

---

### ICD-O Topography Codes (Anatomic Site)

Site Group	ICD-O-3 Site	ICD-O-3 Histology (Type)
<b>Oral Cavity and Pharynx</b>		
Lip	C000-C009	excluding 9050-9055, 9140, 9590-9992
Tongue	C019-C029	
Salivary Gland	C079-C089	
Floor of Mouth	C040-C049	
Gum and Other Mouth	C030-C039, C050-C059, C060-C069	
Nasopharynx	C110-C119	
Tonsil	C090-C099	
Oropharynx	C100-C109	
Hypopharynx	C129, C130-C139	
Other Oral Cavity and Pharynx	C140, C142-C148	

19

---

---

---

---

---

---

---

---

---

---


---

---

### Head and Neck Site Group

- Oral Cavity
- Lip and oral cavity (C00-C05.0)
  - Lip
  - Tongue
  - Gum and other mouth
  - Mouth Subsites
  - Salivary Glands (C07)
  - Tonsil
- Pharynx
  - Oropharynx (C05.1, C05.2, C10)
  - Nasopharynx (C11)
  - Hypopharynx C12.9, C13)
  - Other Pharynx

#### Structures of the Mouth



A.D.A.M. Illustration used with licensed permission.

20

---

---

---

---

---

---

---

---

---

---

---

---

### Head & Neck Histologic Type

- Depends on the location in the oral cavity and neck
- Squamous cell carcinoma
  - Most common: 90% Squamous cell ca of the oral cavity and oropharynx
    - more aggressive depending on the location of the tumor
    - Stage is critical factor for prognosis
- Melanoma mucosal 15-20%
- KS oral mucosa on the palate, gingiva and tongue
- Hodgkin Lymphoma, extranodal, rare, Walderyer ring, palatine tonsil
- Extramedullar myeloid sarcoma, gingiva, 3.5%

Reference: WHO, Pathology & Genetics, H&N Tumors, Tumor of oral cavity, 2005

21

---

---

---

---

---

---

---

---

---

---


---

---

### Distribution by Site: Squamous Cell Carcinoma

General Location	Specific Location	Incidence
Tongue	Lateral surface	26%
	Ventral surface	
Oral Pharynx	Soft palate	23%
	Tonsillar pillars	
Lip	Vermilion surface	20%
Floor of Mouth	Floor of mouth	17%
Gingiva	Gingiva	9%
Buccal Mucosa	Buccal mucosa	3%
Hard Palate	Hard palate	2%

[www.usc.edu/hsc/dental/opath/Chapters/Chapter13\\_Text.html](http://www.usc.edu/hsc/dental/opath/Chapters/Chapter13_Text.html)



22

---

---

---

---

---

---

---

---

---

---

### Head & Neck Histologic Type

- **Basaloid squamous cell carcinoma, Rare**
- **Keratinizing squamous cell carcinoma**
  - **Nasopharynx**
  - Also called WHO type 1
  - Minority of tumors
  - Often EBV-, older age group
- **Nonkeratinizing carcinoma-differentiated**
  - **Nasopharynx**
  - Also called WHO type 2
  - Rare in childhood

Reference: WHO, Pathology & Genetics, H&NTumors, Tumor of oral cavity, 2005

23

---

---

---

---

---

---

---

---

---

---

### Head & Neck Histologic Type

- **Nonkeratinizing carcinoma-undifferentiated**
  - **Nasopharynx**
  - Also called WHO type 3
  - Very rare in US, common in Taiwan and China (EBV endemic area)
- **Papillary squamous cell carcinoma**
  - Rare; precursor lesion unknown
- **Spindle cell carcinoma**
  - Also called sarcomatoid carcinoma or carcinosarcoma
  - Uncommon in larynx; more common elsewhere in upper aerodigestive tract
- **Verrucous carcinoma**
  - Also called Ackerman's tumor
  - Occurs anywhere in upper aerodigestive tract

Reference: WHO, Pathology & Genetics, H&NTumors, Tumor of oral cavity, 2005

24

---

---

---

---

---

---

---

---


---

---



## Oral Cavity

- Histology
- Squamous cell Carcinoma
  - Includes inner lip, tongue, floor of mouth, gingivae, hard palate
    - Associated with tobacco use, especially chewing tobacco or "dip" Heavy alcohol use



<http://seer.cancer.gov/tools/ssm/headneck.pdf>

25

---

---

---

---

---


---

---

---

## Lip (C00.0-C00.9)

- Parts: skin, vermillion border, mucosa, frenulum lip, commissure
  - Lower lip has better prognosis
  - C00.0, .1, .2 external
  - C00.3, .4, .5 mucosa
  - C00.6 commissure
  - C00.8 overlapping



26

---

---

---

---

---


---

---

---

## Lip

- 23% of oral cancer incidence
  - Lower lip > 90%
  - Upper lip 2-8%
  - Commissure 1-2%
- Most common oral cancer (42-45% of cases)
- Rest basal cell, salivary gland, melanoma
- 90% occur on lower lip, usually along vermillion border
- Symptoms: sore that won't heal, lump in lip
- **Risk factors:** chronic sunlight, pipe smoking, cigarette smoking, poor oral hygiene, fair complexion, organ transplant recipients
- Low risk of metastatic extranodal spread; early to adjacent skin, orbicular muscle; late to buccal mucosa, mandible, mental nerve



27

---

---

---


---

---

---

---

---



**T2N0M0 Squamous cell C00.1**


**Basal cell C44.0**

**NR to FCDS**

**Question**  
 Reportability / Primary Site - Head & Neck:  
 If a wedge resection/shoulder resection is performed on the lower lip for SCCA and the path report refers to "lip, NOS" with no mention of vermilion border, is this case reportable?

**Answer**  
 Review the operative and pathology reports, and the physical exam for mention of "mucosal surface" (reportable) or "skin" (not reportable).  
 If neither are mentioned, lip, NOS is reportable per the ICD-O-3 code of C009.

Question: 20021041  
<http://www.cancer.gov/ncimq/ncimq/index.php?page=ncimq&id=20021041&id=20021041>

28 

---

---

---

---

---

---

---

---


---

---

---

---

### Tongue (C01.9 – C02.9)



**Fig. 3 Leukoplakia**

- 28% oral cancer incidence (2007 ACS)
- Est. 7,320 cases USA 2004 (0.3%)
  - China 34,954; India 28,662
- Parts: Tip, anterior 2/3 tongue, ventral & dorsal surface, frenulum linguae
- Symptoms and Diagnosis: Leukoplakia
- Histology: Squamous cell 90% Usually lateral aspect of middle third of tongue
- More likely to metastasize than other intraoral carcinomas (70% have metastases at presentation)
- Spread eventually to floor of mouth and root of tongue
- **Metastases:** ipsilateral subgastric, submandibular, midjugular nodes; may spread directly to lower jugular nodes
- **Poor prognostic factors:** involvement of posterior third of tongue

<http://www.advancedonc.com/tongue.htm>

29

---

---

---

---

---

---

---

---


---

---

---

---

### Anatomy around the Tongue



epiglottis, lingual tonsil, palatine tonsil, tonsillar fossa, sulcus terminalis, bitter, sour, sweet & salt, fungiform, filiform, circumvallate

<http://www.histology.kcbs.ac.uk/ncim/tongue.php>

30

---

---

---

---

---

---

---

---

---

---

---

---

### Squamous cell CA Tongue



<http://www.gastrohep.com/images/image.asp?id=646>

31

---

---

---

---

---


---

---

---

### Gum (C03.0-C03.9)

- Parts: gingiva, alveolar ridge, periodontal
  - C03.0 upper
  - C03.1 lower
  - C03.9 NOS
- Snuff users 50 x risk (92% users male)
  - 2-3 times level of nicotine



32

---

---

---

---

---


---

---

---

### Floor of Mouth (C04.0-C04.9)

- 16% of all oral cancers
- Symptoms
  - Lesion
  - Decreased tongue mobility
- < 50% local at diagnosis



<http://www.histology.leeds.ac.uk/oral/mouth.php>

<http://www.aonology.com/Internet/LinkClick.aspx?linkid=127>  
<http://www.cdc.gov/cancer/npcr/training/nets/module5/>

33

---

---

---

---

---


---

---

---

### Hard Palate (C05.0, C05.8, C05.9)

- Parts: Roof of mouth (NOT soft palate or uvula)
- Histology (74% malignant, 26% benign)
  - Squamous cell 53%
  - Adenocarcinoma 4%
  - Adenoid cystic 15%
  - Anaplastic CA 4%
  - Mucoepidermoid 10%
  - Other 14%
- Reverse smoking
- 70% tumors extend beyond hard palate



<http://www.cdc.gov/cancer/npcr/training/nets/module5/>

34

---

---

---

---

---

---

---

---

### Cheek/Buccal Mucosa (C06.x)

- Parts: Cheek, vestibule, alveolar sulcus, retromolar trigone, minor salivary glands NOS
- Page 33 ICD-O-3: Minor salivary gland tumors can be found anywhere in oral cavity & surrounding organs – code to specific site if noted, else code to C06.9 (NOS)



<http://www.cdc.gov/cancer/npcr/training/nets/module5/>

35

---

---

---

---

---

---

---

---

### Soft Palate

- Squamous cell carcinoma-palate
- 5-6% of intraoral squamous cell carcinoma
- Most common malignancy of palate
- Usually soft palate, 60% male
- Usually involves adjacent tissues at diagnosis (hard palate tumors involve underlying bone)
- 1/3 have metastases to internal jugular, submandibular and retropharyngeal nodes at diagnosis; rarely bilateral
- Pathology report should describe involvement of underlying bone



Photo: Healthline

36

---

---

---

---

---


---

---

---

### 3 Subsites of Pharynx

- **Nasopharynx** (upper part of the pharynx, behind the nose)
- **Oropharynx** (middle part of the pharynx, soft palate the back of the mouth, base of the tongue, and the tonsils)
- **Hypopharynx** (lower part of the pharynx posterior pharyngeal wall, cricoid)



37

---

---

---

---

---

---

---

---


---

---

### Nasopharynx (C11.0-C11.9)

- C11.0 superior wall
- C11.1 posterior wall
- C11.2 lateral wall
- C11.3 anterior wall
- C11.8 Overlapping lesion of nasopharynx
- C11.9 Nasopharynx, NOS

- Swollen or tender lymph nodes
- Difficulty trouble opening the mouth, chewing and swallowing
- Ear infections
- Nasal obstruction or bleeding
- Noticeable nasal "twang" in the voice
- Epstein Barr Virus
- Nonkeratinizing SCC 50+%
- Keratinizing SCC 30%
- Lymphoepithelioma 25% (a variant of SCC)



38




---

---

---

---

---

---

---


---

---

---

### Nasopharynx

- Arises in the nasopharynx (region of nasal cavities)
- Eustachian tubes connect with the upper part of the throat
- Common to the HNSCC



39

---

---

---

---

---

---

---

---

---


---

## Parts of Oropharynx

(C01.9, C05.1, C05.2, C09.x, C10.x)

- **Subsites of Oropharynx**
  - C01.9 Base of tongue
  - C05.1 Soft palate
  - C05.2 Uvula
  - C09.1 Tonsillar fossa
  - C09.2 Tonsillar pillar
  - C09.9 Tonsil, NOS
  - C10.0 Vallecula
  - C10.2 Lateral wall
  - C10.3 Posterior wall
  - C10.9 Oropharynx, NOS

• NOTE C10.1 Anterior surface epiglottis



40

---

---

---

---

---

---

---


---

---

---

## Oropharynx (C10.0-C10.9)

- Originate in the oropharynx, middle part of the throat that includes the soft palate, base of tongue, and tonsils
- Squamous cell carcinoma of the tonsils - HPV



<http://training.seer.cancer.gov/head-neck/anatomy/mouth.html>

41

---

---

---

---

---

---

---

---

---

---

## Oropharynx

### Symptoms

- Persistent sore throat or cough
- Hard or painful swallowing
- Unexpected weight loss
- Vocal changes
- Ear pain
- A lump in the throat, mouth or neck
- Dull chest pain

### Risk Factors

- Smoking and chewing tobacco
- Heavy alcohol use
- Diet low in fruits and vegetables.
- Human papilloma virus (HPV) infection

42

---

---

---

---

---

---

---


---

---

---

### Hypopharynx (C12.9, C13.0-C13.9)

- Tumor in the pyriform sinuses (70%), posterior pharyngeal wall, and postcricoid area (15%).
- Usually frequent Dx with advanced stage at Dx
- Metastasize early due to extensive lymphatic network around the larynx



<http://www.rahuigladwin.com/medimages/index.php?level=picture&id=136>

43

---

---

---

---

---

---


---

---

---

---

### Parts of Hypopharynx (C12.9, C13.x)



- C12.9 Pyriform sinus (most common, most lethal)
- C13.0 Postcricoid
- C13.1 Hypo-pharyngeal aspect of aryepiglottic fold
- C13.2 Posterior wall
- C15.0 Esophagus

44




---

---

---

---

---

---

---

---

---

---

### Salivary Glands (C07.9-C08.9)

#### The Major Salivary Glands

- Parotid: serous, most common
- Submandibular: mucous & serous
- Sublingual tumors are rare and may be difficult to distinguish from minor salivary gland primary tumors of anterior floor of mouth

#### The Minor Salivary Glands

##### Symptoms

- Swelling under the chin or jawbone
- Numbness or paralysis in facial muscles
- Persistent face, chin or neck pain

- **Regional lymph nodes:** nodal metastases usually evident on initial clinical evaluation; low grade tumors rarely metastasize to regional nodes, high grade tumors often do; nodal involvement tends to be orderly from intraglandular to adjacent nodes to upper and midjugular nodes, and occasionally to retropharyngeal nodes; bilateral nodal involvement is rare
- **Metastases:** usually to lungs

#### Risk Factors

- Smoking and chewing tobacco
- Heavy alcohol use

45

<http://www.histology.leeds.ac.uk/oral/salivary.php>

---

---

---

---

---

---

---

---

---

---

## Salivary Gland Histologic Type

- Acinic cell 1-3% of salivary gland tumors #2 childhood salivary gland malignancy after mucoepidermoid carcinoma
- Adenocarcinoma Usually not in glottis May arise from surface epithelium
- Adenoid Cystic : Most common in submandibular, sublingual or minor salivary glands
- Malignant mixed
- Mucoepidermoid **Most common** 2/3 occur in parotid gland& palate
- Squamous Cell
- Schwannoma
  - May arise from facial nerve and present as salivary gland tumor
  - Gross: encapsulated
- Basal cell adenocarcinoma also called basaloid carcinoma
- 1-2% of salivary gland carcinomas
- Cystadenocarcinoma
- Papillary adenocarcinoma <3% of parotid tumors



**Children:** pleomorphic adenoma most common, but more often malignant; most common malignant tumors are mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma

Cancer of the Head and Neck, 4<sup>th</sup> ed., 2000, pg 483

46

---

---

---

---

---

---

---

---


---

---

## Parotid Gland Anatomy (C07.9)

- Largest salivary gland
- Lies between the mandible and sternomastoid and over both
- Lymphatics: Paraparotid & Intraparotid nodes & Superficial & Deep Cervical nodes

### Major Salivary Glands



A.D.A.M. Illustration used with licensed permission.

### Signs & Symptoms

- Facial nerve paralysis
- Pain or facial paresis

47

---

---

---

---

---

---

---


---

---

---

## Parotid Gland – Histologic Type

- Mucoepidermoid carcinoma 30%
  - 2/3 occur in parotid gland
  - Wide age range, mean 49 years, range 15-86 years, no gender predominance
  - Low grade: 15% recur, 5 year survival 90-98%; usually stage I
  - High grade: 25% recur, 5 year survival 50-56%; deaths usually within first 5 years
- Adenocarcinoma
- Malignant pleomorphic adenoma, rare
- Adenoid cystic carcinoma
- Sebaceous carcinoma, rare
- Papillary adenocarcinoma <3% of parotid tumors
- Salivary duct carcinoma
- Carcinosarcoma
- Squamous cell carcinoma, **rare**
  - Most tumors of parotid gland are metastases to intraparotid lymph nodes from primaries in oral cavity, upper aerodigestive tract or skin
  - May represent malignant component of malignant mixed tumor or high grade mucoepidermoid carcinoma
  - Rapid growth with infiltration of surrounding structures, regardless of origin



<http://emedicine.medscape.com/article/1289616-overview#aw2aab6b4>

48

---

---

---

---

---

---

---

---


---

---



### Submandibular Gland: Anatomy

- Large superficial lobe, small deep lobe, size of walnuts (10g.)
- Connect around the mylohyoid
- Superficial lobes lies at the angle of the Jaw



49

---

---

---

---

---


---

---

---

### Sublingual Gland: Anatomy (C08.1)

- Smallest of the major salivary glands, almond shape
- Lies just deep to the floor of mouth mucosa between the mandible & Genioglossus muscle
- No capsule
- Ducts of Rivinus +/- Bartholin's duct
- Sialogram not possible
- Bounded inferiorly by the mylohyoid muscle
- Artery/Vein: Sublingual branch of Lingual & Submental branch of Facial
- Lymphatics: Submandibular nodes



50

---

---

---

---

---


---

---

---

### Minor Salivary Glands: Anatomy

- Unlike the major salivary gland, 500-1,000 approx
- Each salivary unit has its own simple ducts
- Salivary glands in Buccal, Labial, Palatal, Lingual regions
- Tumor sites: Palate, upper lip, cheek



<http://www.utmb.edu/otorel/grnds/Salivary-Gland-2001-01/Salivary-gland-2001-01-ppt.pdf>

51

---

---

---

---

---


---

---

---

## Lymph Nodes

- Head and Neck cancer often spreads to lymph node rich regions in the head, neck, and face



52

---

---

---

---


---

---

---

---

## Head and Neck Lymph Nodes Exam



- **Ant Cervical** Throat, tonsils, post pharynx, thyroid
- **Post Cervical** Back of skull
- **Tonsillar** Tonsils, posterior pharynx
- **Sub-Mandibular** - Floor of mouth
- **Sub-Mental**-Teeth
- **Supra-Clavicular**-Thorax
- **Pre-Auricular**-Ear

53

[http://meded.ucsd.edu/clinicalmed/pe\\_headneckexam.pdf](http://meded.ucsd.edu/clinicalmed/pe_headneckexam.pdf)

---

---

---

---


---

---

---

---

## Lymph Node Level of Head and Neck



- Level Description
- > I Submental, submandibular
  - > II Upper deep cervical
  - > III Middle deep cervical
  - > IV Lower deep cervical
  - > V Posterior triangle
  - > VI Anterior compartment
  - > VII Superior mediastinal
- NOTE: See further information on lymph node levels below.

Image source: Introduction to Head and Neck Sites. In: Greene, F.L., Compton, C.C., Fritz, A.G., et al., editors. AJCC Cancer Staging Atlas. New York: Springer, 2006: 13-18. ©American Joint Committee on Cancer

54

Figure 1-2-1. Lymph Node Levels of Head and Neck

---

---

---

---


---

---

---

---

### Head and Neck Regional Nodes I



1. Submental
  2. Submandibular
  3. Jugular (deep cervical)
  4. Superficial cervical
  5. Supraclavicular
  6. Prelaryngeal\* and paratracheal\*
  7. Retropharyngeal
  8. Parotid
  9. Buccal
  10. Retroauricular and occipital
- \* not shown

55

---

---

---

---

---

---

---

---

---


---

### Head and Neck Regional Nodes II

- 1 Submental
- 2 Submandibular
- 3 Upper jugular
- 4 Lower jugular
- 5 Pretracheal
- 6 Paratracheal
- 7 Prelaryngeal

Not shown:  
Parapharyngeal  
Retropharyngeal

Adapted from MediClip,  
Grant's Atlas Images 4: Head,  
Neck and Cranial Nerves.  
Williams and Wilkins, 1998.



56

---

---

---

---

---

---

---

---

---

---

### Relationship Primary to Nodes

Lymphatic drainage	Likely primary sites
Level I: Includes Submental/Submandibular Submental	Lower lip, chin, anterior oral cavity (including anterior one-third of the tongue and floor of the mouth)
Level I: Submandibular	Upper and lower lips, oral tongue, floor of mouth, facial skin, Maxillary sinus, nasal cavity, oral cavity, submandibular gland
Level II: Includes the superior jugular chain nodes extending from the mandible down to the carotid bifurcation and posterior border of the sternocleidomastoid muscle	Oral cavity and pharynx (including soft palate, base of tongue, and pyriform sinus) Nasal cavity, parotid gland
Level III: Consists of the jugular nodes from the carotid bulb inferiorly to the omohyoid muscle	Oral cavity, pharynx, hypopharynx, larynx, and thyroid
Level IV: Continues from the omohyoid muscle inferiorly to the clavicle	Larynx, hypopharynx, thyroid, cervical esophagus, and trachea
Level V: Represents the posterior border of the sternocleidomastoid anteriorly, the anterior border of the trapezius posteriorly, and the clavicle inferiorly	Nasopharynx, oropharynx

57

<http://www.cancernetwork.com/cancer-management/head-and-neck/article/10165/1802498>

---

---

---

---

---

---

---

---

---

---

## Lymph Node Mets at Diagnosis

- Pyriform sinus – 70%
- Postcricoid area – 40%
- Posterior hypopharynx – 50%
- Nasopharynx – 75%
- Tonsil – 70%
- Base of tongue – 70%
- Soft palate – 30-65%
- Pharyngeal wall – 30-65%
- Paranasal sinuses – 20%
- Medullary ca of thyroid – 50%

58

---

---

---

---

---

---

---

---

---

---

Collaborative Stage Data Collection System Coding Manual and Instructions  
Part I Section 2 Site Specific Sites

### COLLABORATIVE STAGE DATA COLLECTION SYSTEM USER DOCUMENTATION AND CODING INSTRUCTIONS

Collaborative Stage Work Group of the American Joint Committee on Cancer

Part I - General Instructions  
Version 02.03.02

SECTION 2  
Site-Specific Instructions

Effective January 1, 2011 Part I Section 2 Page 1 Version 02.03.02

#### Definitions of Levels for H & N Sites

The definitions of the levels and the lymph node chains included in each level are as follows:

**Level I** (First digit of SS 3) contains the submental and submandibular triangles bounded by the anterior and posterior bellies of the digastric muscle, and the hyoid bone inferiorly, and the body of the mandible superiorly. Lymph node chains at this level:

Submandibular Submental

**Level II** (Middle digit of SS 3) contains the upper jugular lymph nodes and extends from the level of the skull base superiorly to the hyoid bone inferiorly. Lymph node chains at this level:

Jugulo-digastric (subdigastric) Upper deep cervical Upper jugular

**Level III** (Last digit of SS 3) contains the middle jugular lymph nodes from the hyoid bone superiorly to the level of the lower border of the cricoid cartilage inferiorly. Lymph node chains at this level:

Middle deep cervical Mid jugular

**Level IV** (First digit of SS 4) contains the lower jugular lymph nodes from the level of the cricoid cartilage superiorly to the clavicle inferiorly. Lymph node chains at this level:

Jugulo-omohyoid (trapezohyoid)

Lower deep cervical Lower jugular

**Level V** (Middle digit of SS 4) contains the lymph nodes in the posterior triangle bounded by the anterior border of the trapezius muscle posteriorly, the posterior border of the sternocleidomastoid muscle anteriorly, and the clavicle inferiorly. For descriptive purposes, Level V may be further subdivided into:

59

---

---

---

---

---

---


---

---

---

---

## Lymph Nodes



<http://fitnesscares.blogspot.com/2011/04/lymph-nodes-of-head-and-neck.html>

60

---

---

---

---

---

---

---

---

---

---

### Metastasis Site of H&N

- Lymph nodes in the upper part of the neck (Occult Primary)
- Patients with cervical lymph node metastases histologically related to a previously treated primary tumor and patients with lymphomas and adenocarcinoma are excluded
- Most epidermoid carcinomas metastatic to lymph nodes of the upper half of the neck will originate from a head and neck primary site
- Squamous carcinomas metastatic to the lower neck may represent a primary site in the head and neck, esophagus, lung, or genitourinary tract
- Check Metastatic disease Lung, Liver, or bone

<http://www.cancer.gov/cancertopics/pdq/treatment/metastatic-squamous-neck/HealthProfessional>

61

---

---

---

---

---

---

---

---

### Multiple Primary Rules Histology Coding Rules




---

---

---

---

---

---

---

---

### MPH – Priority order

#### Documenting the Primary Site Priority of order

1. Tumor board determination (specialty; general)
2. Staging physician's site assignment (staging form; TNM statement in record)
3. Total resection of primary tumor (physician's statement; final diagnosis from pathology report)
4. No resection—use documentation from
  - Endoscopy; Radiation oncologist; Diagnosing MD; Primary care MD; Other MD; Radiologist-imaging; MD-PE

#### Equivalent Terms (for MP/H rules ONLY)

- Tumor = Mass = Lesion = Neoplasm
- In situ = noninvasive = intraepithelial
- Continuous = contiguous
- Squamous cell carcinoma = squamous cell epithelioma = epidermoid carcinoma
- Type = Subtype = Predominantly = With features of = Major = With \_\_\_\_\_ differentiation

63

---

---

---

---

---

---

---

---

### MP/H Rules: Single Primary

- **M1** Unsure Multiple vs Single Tumor – Unknown number
  - When it is not possible to determine if there is a single tumor or multiple tumors, opt for a single tumor and abstract as a single primary. Prepare as one abstract.
    - Tumor not described as metastasis
- **M2** Single Tumor- One tumor
  - A single tumor is always a single primary.
    - Might be overlapping
    - Tumor not described as metastasis
    - Combination of in situ and invasive

64

---

---

---

---

---

---

---

---

### MP/H Rules: Multiple Primaries

- **M3** Paired sites – Tumors on **right** and **left** sides are **multiple** primaries (Table 1)
- **M4** Lip – Tumors on **UPPER lip** and **LOWER lip** are **multiple** primaries (C00.x)

Column 1: Paired Sites	Column 2: Code
Parotid Glands	C079
Major Salivary Glands	C080; C081
Tonsils	C090; C091; C098; C099
Nasal Cavity	C300
Accessory Sinuses	C310; C312
Middle Ear	C301

- **M5** Gum – Tumors on **UPPER gum** and **LOWER gum** are **multiple** primaries (C03.x)
- **M6** – Tumors in **nasal cavity** and **middle ear** are **multiple** primaries (C30.x)



65

---

---

---

---

---

---

---

---

### MP/H Rules: Multiple Primaries

- **M7** – Tumors with ICD-O-3 topography codes different at 2<sup>nd</sup> (Cxxx) or 3<sup>rd</sup> (Cxxx) character are **multiple** primaries
  - Example
    - C02.1 Tip of tongue
    - C10.0 Vallecula
  - Example
    - C06.0 Cheek mucosa
    - C07.9 Parotid gland
- Timing Rules
  - **M8** - An **invasive** tumor following an **in situ** tumor more than **60 days** after diagnosis is a **multiple** primary
  - **M9** - Tumors diagnosed more than **five (5) years apart** are **multiple** primaries



66

---

---

---

---

---

---

---

---

### MP/H Rules: Multiple Primaries

- **M10** – when histology notes **generic** description WITH more **specific** description it is **SINGLE** primary
  - Cancer/malignant neoplasm, NOS (8000) and another is a specific histology or
  - Carcinoma, **NOS** (8010) *and* another is a **specific** carcinoma or
  - Adenocarcinoma, **NOS** (8140) *and* another is a **specific** adenocarcinoma or
  - Squamous cell carcinoma, **NOS** (8070) *and* another is **specific** squamous cell carcinoma or
  - Melanoma, **NOS** (8720) *and* another is a **specific** melanoma
  - Sarcoma, **NOS** (8800) *and* another is a **specific** sarcoma

67




---

---

---

---

---

---

---

---

### MP/H Rules: Multiple Primaries

- **M11** - Tumors with ICD-O-3 histology codes that are different at the first (**x**xxx), second (**xx**xx) or third (**xxx**x) number are **multiple** primaries.
- **M12** - Tumors that *do not meet* any of the above criteria are abstracted as a single primary.
  - *Note 1:* When an invasive tumor follows an in situ tumor **within 60 days**, abstract as a single primary.
  - *Note 2:* All cases covered by Rule M12 have the **same first 3 number** in ICD-O-3 histology code.
    - Sample: Multifocal tumors in floor of mouth
    - Sample: In situ following invasive > 60 days apart

68




---

---

---

---


---

---

---

---

### Case Scenario: Multiple Primaries



69



<http://www.cdc.gov/cancer/npcr/training/nets/module5>

---

---

---

---

---

---

---

---

## MPH: Histology

Reminder  
Read general rules AND site-specific rules  
Look for equivalent terms  
Most representative specimen

70

---

---

---

---

---

---

---

---

## MP/H Rules: Histology Single Tumor

H1 **No** path/cytology done or **available?**

- Priority
  - Documentation that refers to path
  - Physician's reference to type of cancer
  - CT, PET or MRI
- Code specific term when documented
- Code 8000 or 8010 as stated by physician

H2 **No** path/cytology of **primary** site

- Code info from metastatic site
- Behavior code /3 at primary site

71

---

---

---

---

---

---

---

---

## MP/H Rules: Histology Single Tumor

H3 **One** histologic **type?** – code that

- Do NOT code terms that are not there
- EX: Squamous cell carcinoma = 8070 (NOT nonkeratinizing 8072)
- Do not code 8072 (squamous cell carcinoma non-keratinizing) unless the words "non-keratinizing" actually appear in the diagnosis.

H4 **Invasive** AND **in situ** =  
invasive only

H5 Code the most **specific** histologic term using Chart 1 when there are multiple histologies within the same branch

- Use Chart 1
- Cancer/malignant neoplasm, NOS (8000) and a more specific histology or
- Carcinoma, NOS (8010) and a more specific carcinoma or
- Squamous cell carcinoma, NOS (8070) and a more specific squamous carcinoma or
- Adenocarcinoma, NOS(8140) and a more specific adenocarcinoma or
- Melanoma, NOS (8720) and a more specific melanoma or
- Sarcoma, NOS (8800) and a more specific sarcoma

H6 Code to the **highest** number ICD-O-3 code

72

---

---

---

---

---

---

---

---



## Paired Sites (Chart 1) and Other Multiple Primaries

Head and Neck Equivalent Terms, Definitions, Charts, Tables and Illustrations C000-C148, C300-C329

Table 1—Paired Sites  
Table Instructions: Use this table to determine multiple primary status for sites listed in Column 1.

Column 1: Paired Sites	Column 2: C Code
Parotid Glands	C092
Major Salivary Glands	C080, C081
Tongue	C000, C001, C098, C099
Nasal Cavity	C300
Accessory Sinuses	C310, C312
Middle Ear	C301


Table 2 – Changes to Previous SEER Site Grouping Table

Previous to 2007, tumors in sites on the same row were abstracted as a single primary.

Code	Site Groupings
C01	Base of tongue
C02	Other and unspecified parts of tongue
C05	Palate
C06	Other and unspecified parts of mouth
C07	Parotid gland
C08	Other and unspecified major salivary glands
C09	Tongue
C10	Oropharynx
C12	Pyrimidal tonsil
C13	Epipharynx
C30	Nasal cavity and middle ear
C31	Accessory sinuses

73


## Head and Neck Histology Rules (Chart 1)



74

## MP/H Rules: Histology Single Tumor


Chart 1



75

### Code Most Specific Term

- **Most specific code is toward bottom of chart**
- **Example 1**
  - **Buccal cytology: carcinoma, NOS**
  - **Excision: squamous cell ca -**
  - **Use code 8070**
- **Example 2**
  - **Biopsy: squamous carcinoma**
  - **Resection: spindle cell squamous cell carcinoma**
  - **Use code 8074**



76

---

---

---

---

---

---

---

---


---

---

### Definition – Most Invasive Tumor

- Definition: tumor with greatest continuous extension
  - Invasive > in situ
  - If all are invasive, highest stage
- Layers of squamous tissue (least to most invasive)
  - Epithelium (in situ)
  - Lamina propria\*
  - Submucosa\*
  - Muscularis propria\*

\*except gum and hard palate



http://www.geocities.com/romaniandentistry/images/pacienti/mucosa.gif

77

---

---

---

---

---

---

---

---

---

---

### MPH Rules: Histology Multiple Tumors/Single Tumor

- H7** – same as H1 (no path available)  
Code the histology documented by the physician when there is **no pathology/cytology specimen or the pathology/cytology report is not available.**
- H8** – same as H2 (code from mets tissue)  
Code the histology from the **metastatic** site when there is **no pathology/cytology specimen from the primary site.**
- H9** – same as H3 (code one if only one listed)  
Code the histology when only **one histologic type** is identified.
- H10** – same as H4 (code invasive when in situ + invasive)  
Code the histology of the **most Invasive** tumor.
- H11** – same as H5 (use Chart 1)  
Code the most **specific** histologic term using Chart 1 when there are multiple histologies within the same branch
- H12** – same as H6 (none of the above)  
Code the histology with the **numerically higher** ICD-O-3 code.

78

---

---

---

---

---

---

---

---

---

---

## Abstracting Issues

Determine the correct primary site  
 Overlapping Lesions  
 Unknown Site with positive lymph node  
 Many staging schemas



79

---

---

---

---

---

---

---

---

## Abstracting Issues

ICD-O-3 – **C14.8**

- What is the primary site?
- **Very Important to determine the correct primary site**
- Overlapping Lesions
- **DO NOT USE C76.0**



**Head and Neck, Terms and Definitions**

When the point of origin cannot be determined, use a topography for overlapping sites:

- C02.8 Overlapping lesion of tongue
- C08.8 Overlapping lesion of major salivary glands
- **C14.8** Overlapping lesion of lip, oral cavity, and pharynx

Head and Neck, Squamous Sites, Definitions, Charts, Index and Illustrations  
 ©2008 C148, C149, C150, C151 (Excludes Lymphomas and Leukemias - M-920 - 999) and  
 Report versions M01009 page 18

80

---

---

---

---

---

---

---

---

## H&N SEER Inquiry



**Question** 20110089

Primary site--Head & Neck: What is the correct topography code for squamous cell carcinoma diagnosed from lymph node and deemed to be a head and neck primary but specific site could not be identified? Code C148 or C760?

**Discussion**

**Code C148** is based on note in ICD-O-3 indicating it should be used when a code between C000 and C142 cannot be assigned. Previous SINQ and I&R answers indicated it should be coded to C760.

**Answer**

**Assign code C148**

Last Updated  
 08/08/11

<http://seer.cancer.gov/seerinqury/index.php?page=view&id=20110089&type>



81

---

---

---

---

---

---

---

---



## Head and Neck – CS

### CS Fields

- Tumor Size—standard
- Extension
- TS/Ext Eval—standard
- Lymph Nodes
- LN Eval—standard
- LN Pos—standard
- LN Exam—standard
- Mets at Dx
- Mets Eval—standard

(Refer to the CS Extension table for instructions on coding extension.)

85

### CS Tumor Size

<b>Lip</b>	<b>Other Mouth</b>
• Upper	Buccal Mucosa
• Lower	Salivary Glands
• Other	• Parotid
	• Submandibular
	• Other Salivary
<b>Tongue</b>	<b>Pharynx</b>
• Base	• Oropharynx
• Anterior	• Anterior
<b>Gum</b>	<b>Epiglottis</b>
• Upper	• Nasopharynx
• Lower	• Hypopharynx
• Other	• Other Pharynx
<b>Floor of Mouth</b>	
<b>Palate</b>	
• Hard	
• Soft	

Code the specific tumor size as stated in the medical record. Use code 992 or 994 if the physician's statement about T value is the ONLY information available about the size of the tumor.

---

---

---

---

---

---

---

---

---

---

## Head and Neck – CS Extension & Eval

### General format

- 000 In situ
- 100 Lamina propria/submucosa
- 300 Localized, NOS
- 400-590 Adjacent structures (T3)
- 600-690 Mixed T3-T4 (site specific)
- 700-800 Adjacent structures (T4)
- 950 No evidence of primary tumor (T0)

### CS Eval

- General structure
- 0 clinical only
- 1 invasive techniques, no bx; or needle bx
  - does not meet criteria for pathologic T or N
- 2 autopsy (known or suspected dx)
- 3 pathology
- 5 pre-op tx, clinical eval
- 6 pre-op tx, path eval
- 8 autopsy (dx not suspected)
- 9 unknown, not assessed

86

---

---

---

---

---

---

---

---

---

---

## SITE SPECIFIC FACTORS - SSF's

- Head and Neck – Carcinoma and melanoma
- Lymph nodes
  - Lymph Nodes Levels
  - Upper/Lower Cervical
- Extracapsular Extension
- HPV status
- Thickness/depth
- Schema discriminator

---

---

---

---

---

---

---

---

---

---

### SSF's Head and Neck Sites

- **SSF1 Size of Lymph Nodes – FCDS Required**
  - Except Schema Pharynx other
- SSF2 OBSOLETE - Extracapsular Extension, Lymph Nodes
- SSF3 Levels I-III, Lymph Nodes
- SSF4 Levels IV-V and Retropharyngeal Lymph Nodes
- SSF5 Levels VI-VII and Facial Lymph Nodes
- SSF6 Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes
- SSF7 Upper and Lower Cervical Node Levels
- SSF8 Extracapsular Extension Clinically, Lymph Nodes
- SSF9 Extracapsular Extension Pathologically, Lymph Nodes
- SSF10 HPV (Human Papilloma Virus) Status
- SSF11 Measured Thickness (Depth)

88

---

---

---

---

---

---

---

---

---

---

### SSF's Head and Neck Sites

Schema Number	Schema Name	TNM/SS Required	FCDS Required	COC Additional Required
10	Brachytherapy	1	1	1,4,5,6,9,11
12	Eyeglobe/Antrorse	1	1	1,4,5,6,9
17	Fluoromask	1	1	1,4,5,6,9,11
11	Gum/Lower	1	1	1,4,5,6
15	Gum/Other	1	1	1,4,5,6
11	Gum/Upper	1	1	1,4,5,6
17	Hippopharynx	1	1	1,4,5,6
23	Larynx/Glottis	1	1	1,4,5,6,9
28	Larynx/Other	1	1	1,4,5,6,9
26	Larynx/Subglottic	1	1	1,4,5,6,9
14	Larynx/Supraglottic	1	1	1,4,5,6,9
1	Lip/Lower	1	1	1,4,5,6,9,11
2	Lip/Other	1	1	1,4,5,6,9,11
1	Lip/Upper	1	1	1,4,5,6,9,11
23	Oral/Other	1	1	1,4,5,6,9,11
14	Nasal/Cavity	1,25	1,25	1,3,4,5,6,8,10
10	Oropharynx	1	1	1,3,4,5,6,8,10
10	Palate/Hard	1	1	1,3,4,5,6,8,11
21	Palate/Soft	1	1	1,3,4,5,6,8,10
16	Pharynx/Hypopharynx	1,25	1,25	1,3,4,5,6,8,10
19	Pharynx/Other	None	None	1,3,4,5,6,8,10
29	Salivary/Duct/Other	1	1	1,4,5,6,9
28	Submandibular/Gland	1	1	1,4,5,6,9
9	Tongue/Anterior	1	1	1,4,5,6,9,11
7	Tongue/Back	1	1	1,4,5,6,9,10

89

---

---

---

---

---

---

---

---

---

---

### Site-Specific Factor 1 Size of Involved Node - Note

- Required by FCDS & COC
- Code size of NODE, not size of metastasis
- Code largest diameter measured clinically or pathologically
- Code regional nodes only
- Size format same as tumor size with extra choices
- 996 Described as less than 6 cm
- 997 Described as more than 6 cm

90

---

---

---

---

---

---

---

---

---

---

## Treatment



---

---

---

---

---

---

---

---

## Head and Neck Multidisciplinary Approach

- Treatment depends on:
- Site
- Location
- Histology
- Stage
- Node Status
- Competence
- Convenience
- Cost
- Compliance
- Complications

Head & Neck Cancer: A Multidisciplinary Approach, 2<sup>nd</sup> ed., pg 275

92

---

---

---

---

---

---

---

---

## Treatment Strategies

- **Surgery**
  - First choice when possible, but often limited by disfigurement and preservation of organ function such as speech and swallowing
- **Radiation**
  - Most head and neck cancer is sensitive to radiation while preserving organ function
    - Daily treatment lasts for 6-8 weeks
    - Side effects can be severe; permanent dry mouth, oral ulcers,
    - osteoradionecrosis of the mandible, altered taste, weight loss, and tooth decay
- **Chemotherapy**
  - Can have dramatic response to treatment, but is often not a durable response
  - Side effects can also be severe; decreased blood counts, anemia, infections, weight loss, nausea, vomiting, and hair loss.
  - Newer targeted therapies have lower side effects

93

---

---

---

---

---

---

---

---

### Treatment options for Head and Neck Cancer

#### Disease Extent

- T1N0-1 or T2 N0
- T2N1 or T3-4 or N2-3
- Recurrent or M1

Early stages: Surgery or RT  
 Advanced Stages: Chemo/RT  
 or surgery followed by  
 RT/Chemorx  
 Very Advanced: RT and  
 Chemorx

#### Treatment

- Surgery or RT
- Combined modality
- Surgery and/or RT
- Combined modality
- Chemotherapy
- Clinical Trials

94

---

---

---

---

---

---

---

---

### Common Treatment by Site

Primary	Early	Advanced
• Lip	R/S	R
<i>Oral Cavity</i>		
• Oral tongue	S/R	R or S+R
• Floor of mouth	S/R	R or S+R
• Gingiva	S	S+R
• Hard Palate	S	S+R
• Buccal mucosa	S/R	S+R
• Retromolar trigone	S	S+R

95

---

---

---

---

---

---

---

---

### Common Treatment by Site

Primary	Early	Advanced
<i>Oropharynx</i>		
• Soft palate	R	R
• Tonsillar fossa	S/R	S+R
• Ant. tonsillar pillar	S/R	S+R
• Pharyngeal tongue	S/R	R
• Pharyngeal wall	R	S+R
<i>Hypopharynx</i>		
• Pyriform sinus	S/R	R or S+R
• Posterior pharynx	R	R

96

---

---

---

---


---

---

---

---






---

---

---

---

---


---

---

---

### Lip

- Surgical removal of tissue
  - Moh's procedure
- Frozen section and cutting using H&E
- Reconstructive surgery (reconstruct surgical defect)
- Chemo/Radiation if needed
- Rarely neck dissection



[http://www.oncohealth.org/files/onhealth/images/img/img\\_patient\\_mohs\\_method.pdf](http://www.oncohealth.org/files/onhealth/images/img/img_patient_mohs_method.pdf)

98

---

---

---

---

---

---

---

---

### Surgery: Oral Cavity

**Key:**  
 X = complete  
 \* = partial  
 o = optional

#### Tissues Removed

Types of Surgery	Tumor Destruction	Tumor Only	Organ	Lymph Nodes	Other Organs
Cryosurgery	*				
Electrocautery (without specimen)	-				
Laser surgery without specimen	*				
Laser surgery with specimen		*X			
Excisional biopsy			*		
Local surgical excision examples: hemiglossectomy, tonsillectomy, alveolectomy			X		
Radical excision examples: total glossectomy		X	*		*
Local or radical excision with radical neck dissection examples: en bloc resection, Commodo procedure		X	X		*
Radical neck dissection only				X	
Surgery of regional/distant sites/nodes only					-

<http://training.seer.cancer.gov/head-neck/treatment/surgery/oral.html>

99

---

---

---

---

---

---

---

---

### Salivary Gland Treatment Decisions

	T1, T2 Low grade	T1, T2 High grade	T3	T4
Parotid gland	Complete resection	Resection Neck dissect.; RT if LN pos	Resection Neck dissect.; RT if LN pos	Resection Resection of other organs Neck if pos
Submandibular	Complete resection	Wide excision RT	Wide excision, nerves if pos RT	Excision of involved areas RT

100

---

---

---

---

---

---

---

---

### Hypopharynx & Nasopharynx RX

- Surgery
- Combination Radiation & Chemotherapy
- Regular screening
- Surgery
- Combination Radiation & Chemotherapy
- Regular screening

101

---

---

---

---

---

---

---

---

### Chemotherapy

- Classical chemotherapy is directed at metabolic sites essential to cell replication
- Tumor cells replicate more frequently than normal cells
  - However, standard chemotherapy does not specifically recognize cancer cells
  - Highest morbidities in rapidly dividing cells: bone marrow, GI mucosa, and hair cells

102

---

---

---

---

---

---

---

---

## Chemotherapy on H&N (MACH-NC) Results

Meta-Analysis of Chemotherapy on H&N  
MACH-NC Results

Timing of Chemotherapy	Risk Reduction	P-value	Absolute Benefits (5yrs)
Adjuvant	-6%	NS	-2%
Induction	4%	NS	2%
Concomitant	19%	<0.00001	8%
Total	12%	<0.00001	5%

NCCN; Lancet 2000; 355:949

103

---

---

---

---

---

---

---

---

---

---

---

---

## Chemotherapy

- Single
- Targeted **Cetuximab** (Erbix)
- Combinations
- NCCN Guidelines
- New Treatments
- Targeted Chemotherapy: A specific receptor on the surface of common head and neck cancer cells is called Epidermal Growth Factor Receptor (EGFR)
  - EGFR levels increase in advanced stage tumors and in poorly differentiated tumors
  - Cetuximab is an antibody against the EGFR receptor which can stop cell cycle progression and induce cell death.



<http://www.azoncology.com/internet/>

104

---

---

---

---

---

---

---

---

---

---

---

---

## Types of Chemotherapy

### Single drugs

- Bleomycin
- Camptosar (Ifosfamide)
- Carboplatin
- Cisplatin
- Docetaxel (Taxotere)
- 5FU
- Irinotecan
- Methotrexate
- Paclitaxel (Taxol)
- Vinorelbine (Navelbine)

### Combinations

- **5FU/Cisplatin**
- Docetaxel/Platinum
- Docetaxel/5FU
- Docetaxel/5FU/Platinum
- Erbix (cetuximab) – combined with radiation – FDA approved February 2006



<http://www.medscape.com/viewarticle/753061>

105

---

---

---

---

---

---

---

---

---

---

---

---

## Chemo-XRT

### Theoretical Benefits of Chemo-XRT

- Inhibiting repair of lethal and sublethal damage induced by radiotherapy
- Radiosensitizing hypoxic cells
- Reducing tumor burden, leading to an improved blood supply
- Redistributing tumor cells to a more radiosensitive cell cycle phase
- Inducing apoptosis

---

---

---

---

---

---

---

---

## Radiation Therapy

- Standard Radiation
  - Hyperfractionated, accelerated
- Intensity-Modulated Radiotherapy (IMRT)
- Brachytherapy- Not widely used for H&N cancers

107

---

---

---

---

---

---


---

---

## IMRT Head & Neck

Intensity Modulated Radiation Therapy means that the intensity of the radiation beam in a given treatment field is varied via multiple multileaf blocking arrangements called segments.

- Intensity modulation combined with multiple fields (radiation beam angles) or arcs allows for conformal radiotherapy (ie high radiation isodose lines conform to the target volume and spare normal tissues).



[http://www.centracare.com/specialty\\_centers/cancer/images/imrt\\_head\\_neck.jpg](http://www.centracare.com/specialty_centers/cancer/images/imrt_head_neck.jpg)

<http://www.azoncology.com/internet/>

108

---

---

---

---


---

---

---

---

### IMRT - Hypopharynx



109

<http://www.azoncology.com/internet/>

---

---

---

---

---

---

---

---

### IGRT – Image Guided Radiation Therapy

- Daily X-rays or CT scans are performed and overlaid with the planning CT
- Millimeter adjustments are made with automatic couch position shifts
- Treatment becomes more accurate and consequently smaller target volumes will result in less side effects



110

<http://www.azoncology.com/internet/>

---

---

---

---

---

---

---

---

### IGRT – MV X-rays



111

<http://www.azoncology.com/internet/>

---

---

---

---

---

---

---

---



NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)

# Head and Neck Cancers

Version 2.2011  
NCCN.org

---

---

---

---

---

---

---

---

---

---

---

---

National Comprehensive Cancer Network®
 

## NCCN Guidelines™ Version 1.2011

### Head and Neck Cancers

**PRINCIPLES OF SYSTEMIC THERAPY**

The choice of chemotherapy should be individualized based on patient characteristics (performance status, goals of therapy).

**Squamous Cell Cancers**  
Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic larynx, Supraglottic larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary:

**Primary Systemic Therapy + concurrent RT**

- Cisplatin alone (preferred) (category 1)
- Cetuximab (category 1)
- ~~Fluoropyrimidines~~
- Cisplatin/paclitaxel
- Cisplatin/infusional 5-FU
- Carboplatin/infusional 5-FU
- Carboplatin/paclitaxel (category 2B)

**Postoperative Chemoradiation**

- Cisplatin alone (category 1 for high risk)

**Induction/Sequential chemotherapy**

- Docetaxel/cisplatin/5-FU (category 1 if induction is chosen)
- Following induction, agents to be used with concurrent chemoradiation typically include weekly platinum, weekly taxanes, or cetuximab.

\*Induction chemotherapy should only be done in a tertiary setting.

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

CHEM-A

113

---

---

---

---

---

---

---

---

---

---

---

---

National Comprehensive Cancer Network®
 

## NCCN Guidelines™ Version 1.2011

### Very Advanced Head and Neck Cancer

**PRINCIPLES OF RADIATION THERAPY**

**Concurrent chemoradiation (preferred)**

**Conventional fractionation:**

- Primary and gross adenopathy: ≥ 70 Gy (2.0 Gy/fraction)
- Neck
  - Uninvolved nodal stations: 44-64 Gy (1.6-2.0 Gy/fraction)

**Chemoradiation**

Based on published data, concurrent chemoradiation most commonly uses conventional fractionation at 2.0 Gy per fraction to ≥ 70 Gy in 7 wks with single agent cisplatin given every 3 weeks. Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin; altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach. concurrent chemoradiation carries a high toxicity burden; altered fractionation or multiagent chemotherapy will likely further increase the toxicity burden. For any chemoradiation approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration. Chemoradiation should be performed by an experienced team and should include substantial supportive care.

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

ADV-A

114

---

---

---

---

---

---

---

---

---

---

---

---

**NCCN Guidelines™ Version 1.2011**  
**Cancer of the Oropharynx**

Base of tongue/tonsil/posterior pharyngeal wall/soft palate

**CLINICAL STAGING**

Any T, N2-3

**TREATMENT OF PRIMARY AND NECK**

Concurrent systemic therapy/RT cisplatin (category 1) preferred or  
**Induction chemotherapy followed by RT or chemo/RT (category 2B)**

Primary site: Complete clinical response → Residual tumor in neck → Post-treatment evaluation → Negative → Observe; Positive → Neck dissection

Primary site: Salvage surgery ± neck dissection as indicated

Primary site: Excision of primary, ipsilateral or bilateral neck dissection → No adverse features → Follow-up (See FOLL-A); Extracapsular spread and/or positive margin → Chemo/RT (category 1)

Primary site: Excision of primary and bilateral neck dissection → Adverse features → RT or Consider chemo/RT

Multimodality clinical trials

**ADJUVANT TREATMENT**

Neck dissection

Follow-up (See FOLL-A)

Chemo/RT (category 1)

RT or Consider chemo/RT

ORPH-4

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

115

---

---

---

---

---

---

---

---

---

---

**NCCN Guidelines™ Version 1.2011**  
**Cancer of the Oral Cavity**

Buccal mucosa, floor of mouth, anterior tongue, alveolar ridge, retromolar trigone, hard palate

**CLINICAL STAGING**

T3, N0; T4a, Any N; T1-3, N1-3

**TREATMENT OF PRIMARY AND NECK**

N0, N1, N2a-b, N3 → Surgery → Excision of primary, ipsilateral or bilateral neck dissection ± contralateral neck dissection (guided by tumor thickness, extent of disease) → No adverse features → RT (optional); Adverse features → Chemo/RT (preferred) (category 1) or Re-excision or Persistent disease (See ADV-2)

N2c (bilateral) → Excision of primary and bilateral neck dissection → Adverse features → RT or Consider chemo/RT

**ADJUVANT TREATMENT**

RT (optional)

Chemo/RT (preferred) (category 1) or Re-excision or Persistent disease (See ADV-2)

RT or Consider chemo/RT

OR-3

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

116

---

---

---

---

---

---

---

---

---

---

**NCCN Guidelines™ Version 1.2011**  
**Very Advanced Head and Neck Cancer**

**PRINCIPLES OF RADIATION THERAPY**

**Concurrent chemoradiation (preferred)**

**Conventional fractionation:**

- Primary and gross adenopathy: ≥ 70 Gy (2.0 Gy/fraction)
- Neck
- Uninvolved nodal stations: 44-64 Gy (1.6-2.0 Gy/fraction)

**Chemoradiation**

Based on published data, concurrent chemoradiation most commonly uses conventional fractionation at 2.0 Gy per fraction to ≥ 70 Gy in 7 wks with single agent cisplatin given every 3 wks at 100 mg/m<sup>2</sup> × 3 doses. Other fraction sizes (eg, 1.3 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin; altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach. In general, the use of concurrent chemoradiation carries a high toxicity burden; altered fractionation or multiagent chemotherapy will likely further increase the toxicity burden. For any chemoradiation approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration. Chemoradiation should be performed by an experienced team and should include substantial supportive care.

ADVA

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

117

---

---

---

---

---

---

---

---

---

---

NCCN Guidelines™ Version 1.2011  
Head and Neck Cancers

PRINCIPLES OF SYSTEMIC THERAPY

The choice of chemotherapy should be individualized based on patient characteristics (performance status, goals of therapy).

Nasopharynx

Chemoradiation followed by adjuvant chemotherapy  
• Cisplatin + RT followed by Cisplatin/5-FU (category 1)

Recurrent, Unresectable or Metastatic (incurable)

Combination therapy  
• Cisplatin or carboplatin  
+ 5-FU + cetuximab  
(non-nasopharyngeal)  
(category 1)

• Cisplatin or carboplatin  
+ docetaxel or paclitaxel  
• Cisplatin/cetuximab  
(non-nasopharyngeal)  
• Cisplatin + 5-FU

Single agent

• Cisplatin  
• Carboplatin  
• Paclitaxel  
• Docetaxel  
• 5-FU  
• Methotrexate

• Ifosfamide  
• Bleomycin  
• Gemcitabine  
(nasopharyngeal)  
• Cetuximab  
(non-nasopharyngeal)

© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. CHEM-A

118

---

---

---

---

---

---

---

---


---

---

---

---

NCCN Guidelines™ Version 1.2011  
Very Advanced Head and Neck Cancer



© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. ADV-2

119

---

---

---

---

---

---

---

---


---

---

---

---

NCCN Guidelines™ Version 1.2011  
Very Advanced Head and Neck Cancer



© 2011 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. ADV-2

120

---

---

---

---

---

---

---

---

---

---

---

---



### Clinical Trials



- Oral Cancer Adjuvant Therapy (OCAT) Trial – Phase III Mouth Neoplasms
- Erlotinib Prevention of Oral Cancer (EPOC)
- Excision Limits of Oral Cavity Tumor by Narrow Band Imaging
- TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
- Lyophilized Black Raspberries in Preventing Oral Cancer in High-Risk Patients Previously Diagnosed With Stage I-IV or In Situ Head and Neck Cancer
- Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
- Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT)
- IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC

<http://clinicaltrials.gov/search/open/condition=%22Mouth+Neoplasms%22>

121

---

---

---

---

---

---

---

---



### TEXT DOCUMENTATION

DEFENSIVE ABSTRACTING  
CYA - Cover your abstract

Support all codes and dates with supplemental text - primary, histology, staging workup, Ext of Disease, First course of RX

122

---

---

---

---


---

---

---

---

### Any Questions?



123

---

---

---

---


---

---

---

---

Happy Valentines



124

NEXT WEBCAST: To be announced

---

---

---

---

---

---

---

---